Prevalence of CD20 + cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011–2018) in the USA

Trenton S. Ewing, Jason Bradley Pieper, Adam W. Stern

Research output: Contribution to journalReview article

Abstract

Background: Limited information is known about the baseline frequency of canine CD20 positive ( + ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published. Objectives: To characterize the baseline frequency of CD20 + staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator. Animals: Skin biopsies from 24 client-owned animals diagnosed with cutaneous epitheliotropic lymphoma were assessed. Methods and materials: A retrospective review of medical records from 2011 to 2018. Clinical histories and previous histological and immunohistochemical slides were collected from 24 dogs and additional immunohistochemical staining was performed as needed to assess cases of cutaneous epitheliotropic T-cell lymphoma for CD3, CD20, CD79a and PAX5 staining characteristics. Staining characteristics were assessed for their statistical relationship to median survival time. Results: Overall median survival time was 189 days following the onset of clinical signs and 99 days following definitive diagnosis; 54% of cases had CD20 + staining. There was no statistically significant correlation between staining characteristics and median survival time from onset of signs (P = 0.54) or from diagnosis (P = 0.61). Conclusions and clinical significance: Canine cutaneous epitheliotropic lymphoma has a higher instance of CD20 positivity than documented previously. This indicates that CD20 staining may be unsuitable to differentiate T-cell and B-cell cutaneous epitheliotropic lymphoma. This also may have therapeutic implications with the advent of canine CD20 monoclonal antibody therapies.

Original languageEnglish (US)
Pages (from-to)51-e14
JournalVeterinary dermatology
Volume30
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Cutaneous T-Cell Lymphoma
lymphoma
T-lymphocytes
Dogs
Staining and Labeling
mycosis fungoides
Canidae
dogs
Lymphoma
Skin
therapeutics
staining
skin (animal)
B-lymphocytes
Medical Records
biopsy
monoclonal antibodies
animals
B-Lymphocytes
Monoclonal Antibodies

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Prevalence of CD20 + cutaneous epitheliotropic T-cell lymphoma in dogs : a retrospective analysis of 24 cases (2011–2018) in the USA. / Ewing, Trenton S.; Pieper, Jason Bradley; Stern, Adam W.

In: Veterinary dermatology, Vol. 30, No. 1, 01.02.2019, p. 51-e14.

Research output: Contribution to journalReview article

@article{ef1944dd396c42679f950a1bc4a7ec3c,
title = "Prevalence of CD20 + cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011–2018) in the USA",
abstract = "Background: Limited information is known about the baseline frequency of canine CD20 positive ( + ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published. Objectives: To characterize the baseline frequency of CD20 + staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator. Animals: Skin biopsies from 24 client-owned animals diagnosed with cutaneous epitheliotropic lymphoma were assessed. Methods and materials: A retrospective review of medical records from 2011 to 2018. Clinical histories and previous histological and immunohistochemical slides were collected from 24 dogs and additional immunohistochemical staining was performed as needed to assess cases of cutaneous epitheliotropic T-cell lymphoma for CD3, CD20, CD79a and PAX5 staining characteristics. Staining characteristics were assessed for their statistical relationship to median survival time. Results: Overall median survival time was 189 days following the onset of clinical signs and 99 days following definitive diagnosis; 54{\%} of cases had CD20 + staining. There was no statistically significant correlation between staining characteristics and median survival time from onset of signs (P = 0.54) or from diagnosis (P = 0.61). Conclusions and clinical significance: Canine cutaneous epitheliotropic lymphoma has a higher instance of CD20 positivity than documented previously. This indicates that CD20 staining may be unsuitable to differentiate T-cell and B-cell cutaneous epitheliotropic lymphoma. This also may have therapeutic implications with the advent of canine CD20 monoclonal antibody therapies.",
author = "Ewing, {Trenton S.} and Pieper, {Jason Bradley} and Stern, {Adam W.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/vde.12703",
language = "English (US)",
volume = "30",
pages = "51--e14",
journal = "Veterinary Dermatology",
issn = "0959-4493",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prevalence of CD20 + cutaneous epitheliotropic T-cell lymphoma in dogs

T2 - a retrospective analysis of 24 cases (2011–2018) in the USA

AU - Ewing, Trenton S.

AU - Pieper, Jason Bradley

AU - Stern, Adam W.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Limited information is known about the baseline frequency of canine CD20 positive ( + ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published. Objectives: To characterize the baseline frequency of CD20 + staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator. Animals: Skin biopsies from 24 client-owned animals diagnosed with cutaneous epitheliotropic lymphoma were assessed. Methods and materials: A retrospective review of medical records from 2011 to 2018. Clinical histories and previous histological and immunohistochemical slides were collected from 24 dogs and additional immunohistochemical staining was performed as needed to assess cases of cutaneous epitheliotropic T-cell lymphoma for CD3, CD20, CD79a and PAX5 staining characteristics. Staining characteristics were assessed for their statistical relationship to median survival time. Results: Overall median survival time was 189 days following the onset of clinical signs and 99 days following definitive diagnosis; 54% of cases had CD20 + staining. There was no statistically significant correlation between staining characteristics and median survival time from onset of signs (P = 0.54) or from diagnosis (P = 0.61). Conclusions and clinical significance: Canine cutaneous epitheliotropic lymphoma has a higher instance of CD20 positivity than documented previously. This indicates that CD20 staining may be unsuitable to differentiate T-cell and B-cell cutaneous epitheliotropic lymphoma. This also may have therapeutic implications with the advent of canine CD20 monoclonal antibody therapies.

AB - Background: Limited information is known about the baseline frequency of canine CD20 positive ( + ) cutaneous epitheliotropic T-cell lymphoma. A single canine case report has been published. Objectives: To characterize the baseline frequency of CD20 + staining in cases of canine cutaneous epitheliotropic T-cell lymphoma; to assess its values as a prognostic indicator. Animals: Skin biopsies from 24 client-owned animals diagnosed with cutaneous epitheliotropic lymphoma were assessed. Methods and materials: A retrospective review of medical records from 2011 to 2018. Clinical histories and previous histological and immunohistochemical slides were collected from 24 dogs and additional immunohistochemical staining was performed as needed to assess cases of cutaneous epitheliotropic T-cell lymphoma for CD3, CD20, CD79a and PAX5 staining characteristics. Staining characteristics were assessed for their statistical relationship to median survival time. Results: Overall median survival time was 189 days following the onset of clinical signs and 99 days following definitive diagnosis; 54% of cases had CD20 + staining. There was no statistically significant correlation between staining characteristics and median survival time from onset of signs (P = 0.54) or from diagnosis (P = 0.61). Conclusions and clinical significance: Canine cutaneous epitheliotropic lymphoma has a higher instance of CD20 positivity than documented previously. This indicates that CD20 staining may be unsuitable to differentiate T-cell and B-cell cutaneous epitheliotropic lymphoma. This also may have therapeutic implications with the advent of canine CD20 monoclonal antibody therapies.

UR - http://www.scopus.com/inward/record.url?scp=85059888903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059888903&partnerID=8YFLogxK

U2 - 10.1111/vde.12703

DO - 10.1111/vde.12703

M3 - Review article

C2 - 30474245

AN - SCOPUS:85059888903

VL - 30

SP - 51-e14

JO - Veterinary Dermatology

JF - Veterinary Dermatology

SN - 0959-4493

IS - 1

ER -